
Sign up to save your podcasts
Or


For years, an indeterminate thyroid biopsy meant diagnostic surgery but molecular testing is now changing that reality entirely. On this episode of the BackTable ENT podcast, Dr. Ashley Agan interviews endocrinologist Dr. Erik Alexander about how molecular testing and a systematic, layered approach to thyroid nodule evaluation are reducing diagnostic surgeries and enabling more individualized patient care.
---
Get the BackTable app
https://www.backtable.com/app
---
This podcast is supported by
Veracyte
https://www.veracyte.com/
---
Timestamps
00:00 - Introduction
02:48 - Incidence, Presentation, and Workup of Thyroid Nodules
06:26 - Hormonal Impact and Indications for FNA
10:49 - FNA workflow and Bethesda Categories
16:10 - Role of Molecular Testing for Indeterminate Nodules
19:59 - Evolution of Molecular Testing and Afirma
23:51 - Basics of DNA based Testing and RNA based Testing
28:34 - Comparing DNA based and RNA Based Testing
32:10 - Utility of Molecular Testing and Sampling Techniques
35:55 - Cost Coverage and Practical Limits
39:20 - Clinical Implications and Future Impact
42:00 - Final Takeaways
---
More about this episode
Together they walk through the full evaluation pathway, including ultrasound risk stratification using the TI-RADS criteria, the role of TSH testing, and how FNA indications have shifted from biopsying every solid nodule to a more selective, risk-adapted approach. The discussion covers the Bethesda classification system and addresses why the one-third of patients landing in indeterminate categories (Bethesda III, IV, and V) have historically been the most challenging and most overtreated group. The conversation then explores molecular diagnostics as an additional layer of risk assessment, highlighting key differences between DNA-based mutation panels and RNA-based expression classifiers. Dr. Alexander also discusses practical considerations like insurance coverage, sampling technique, turnaround time, and the future potential of molecular testing to move beyond diagnosis toward individualized prognosis.
---
Resources
American College of Radiology: TI-Rads Guidelines
https://edge.sitecorecloud.io/americancoldf5f-acrorgf92a-productioncb02-3650/media/ACR/Files/RADS/TI-RADS/TI-RADS-Assessment-Categories.pdf
American Thyroid Association - Nodule Guidelines
https://pmc.ncbi.nlm.nih.gov/articles/PMC4739132/
Bethesda System for Reporting Thyroid Ctyopathology
https://www.ncbi.nlm.nih.gov/books/NBK278969/table/thyroid-nod-canc-eld.T.bethesda_system_f/
---
BackTable ENT & Allergy is the go-to podcast for otolaryngologists, allergists, and head and neck surgeons.
Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/app
By BackTable4.9
5656 ratings
For years, an indeterminate thyroid biopsy meant diagnostic surgery but molecular testing is now changing that reality entirely. On this episode of the BackTable ENT podcast, Dr. Ashley Agan interviews endocrinologist Dr. Erik Alexander about how molecular testing and a systematic, layered approach to thyroid nodule evaluation are reducing diagnostic surgeries and enabling more individualized patient care.
---
Get the BackTable app
https://www.backtable.com/app
---
This podcast is supported by
Veracyte
https://www.veracyte.com/
---
Timestamps
00:00 - Introduction
02:48 - Incidence, Presentation, and Workup of Thyroid Nodules
06:26 - Hormonal Impact and Indications for FNA
10:49 - FNA workflow and Bethesda Categories
16:10 - Role of Molecular Testing for Indeterminate Nodules
19:59 - Evolution of Molecular Testing and Afirma
23:51 - Basics of DNA based Testing and RNA based Testing
28:34 - Comparing DNA based and RNA Based Testing
32:10 - Utility of Molecular Testing and Sampling Techniques
35:55 - Cost Coverage and Practical Limits
39:20 - Clinical Implications and Future Impact
42:00 - Final Takeaways
---
More about this episode
Together they walk through the full evaluation pathway, including ultrasound risk stratification using the TI-RADS criteria, the role of TSH testing, and how FNA indications have shifted from biopsying every solid nodule to a more selective, risk-adapted approach. The discussion covers the Bethesda classification system and addresses why the one-third of patients landing in indeterminate categories (Bethesda III, IV, and V) have historically been the most challenging and most overtreated group. The conversation then explores molecular diagnostics as an additional layer of risk assessment, highlighting key differences between DNA-based mutation panels and RNA-based expression classifiers. Dr. Alexander also discusses practical considerations like insurance coverage, sampling technique, turnaround time, and the future potential of molecular testing to move beyond diagnosis toward individualized prognosis.
---
Resources
American College of Radiology: TI-Rads Guidelines
https://edge.sitecorecloud.io/americancoldf5f-acrorgf92a-productioncb02-3650/media/ACR/Files/RADS/TI-RADS/TI-RADS-Assessment-Categories.pdf
American Thyroid Association - Nodule Guidelines
https://pmc.ncbi.nlm.nih.gov/articles/PMC4739132/
Bethesda System for Reporting Thyroid Ctyopathology
https://www.ncbi.nlm.nih.gov/books/NBK278969/table/thyroid-nod-canc-eld.T.bethesda_system_f/
---
BackTable ENT & Allergy is the go-to podcast for otolaryngologists, allergists, and head and neck surgeons.
Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/app

32,066 Listeners

14,298 Listeners

19 Listeners

21 Listeners

87,554 Listeners

2,450 Listeners

112,330 Listeners

7 Listeners

9,268 Listeners

6,071 Listeners

29,328 Listeners

16,328 Listeners

2,498 Listeners

11,431 Listeners

1,632 Listeners